Form 4: Alumis Director Srinivas Akkaraju Granted Stock Options

Alumis Inc. Director Srinivas Akkaraju was granted 49,800 stock options with an exercise price of $4.10, vesting over one year or upon the 2026 annual stockholder meeting.

Summary

• Director Srinivas Akkaraju of Alumis Inc. (ALMS) was granted 49,800 stock options.
• The options have an exercise price of $4.10 per share.
• The grant date for these options was July 30, 2025.
• The options expire on July 29, 2035.
• The shares underlying the option will vest on the first anniversary of the grant date (July 30, 2026).
• Alternatively, the shares will be fully vested on the date of Alumis Inc.'s 2026 annual stockholder meeting, if earlier.
• Vesting is contingent upon Mr. Akkaraju's continuous service with the company.
• The options will also vest in full upon a Change in Control, subject to continuous service.
• Following this transaction, Mr. Akkaraju beneficially owns 49,800 derivative securities directly.

Sentiment

Score: 7

Explanation: The filing reports a standard equity grant to a director, which is a positive for aligning interests but does not contain information that would significantly alter the company's financial outlook or operations. It's a routine governance disclosure.

Positives

• Granting of stock options to a director aligns their interests with those of shareholders, incentivizing long-term performance.
• The options have a 10-year expiration period, providing a long window for potential value realization.
• Accelerated vesting upon a Change in Control provides an additional incentive for strategic transactions.

Risks

• The value of the options is subject to the future performance of Alumis Inc.'s stock price.
• Vesting is contingent on continuous service, meaning the options could be forfeited if the director's service terminates before vesting conditions are met.

Future Outlook

The stock options are subject to a vesting schedule, with shares vesting on the first anniversary of the grant date (July 30, 2026) or potentially earlier on the date of the Issuer's 2026 annual stockholder meeting, contingent on continuous service. Full vesting also occurs upon a Change in Control.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as other sectors, to align the interests of board members with long-term shareholder value creation. This practice is particularly prevalent in growth-oriented companies like Alumis Inc.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice across publicly traded companies, including those in the biotechnology sector.
• The vesting schedule (one year or 2026 annual meeting) and 10-year expiration period are typical for director equity grants, comparable to practices at companies like Biogen Inc. or Gilead Sciences, which often use similar long-term incentive structures to retain and motivate key personnel.
• The inclusion of a Change in Control vesting clause is also a common feature in equity incentive plans, providing protection and incentive in M&A scenarios, similar to provisions seen in plans at companies such as Vertex Pharmaceuticals or Amgen Inc.

Corporate Governance

Related Party Transactions

• The grant of 49,800 stock options to Srinivas Akkaraju, a director of Alumis Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial interests with shareholder value creation, as the options gain value only if the stock price increases. It also represents a form of non-cash compensation that could lead to dilution upon exercise, though this is a standard practice.
• Employees: No direct impact on employees is mentioned.
• Customers: No direct impact on customers is mentioned.
• Suppliers: No direct impact on suppliers is mentioned.
• Creditors: No direct impact on creditors is mentioned.

Next Steps

• The granted options will vest on July 30, 2026, or potentially earlier on the date of Alumis Inc.'s 2026 annual stockholder meeting, subject to continuous service.
• The options will expire on July 29, 2035, if not exercised.

Key Dates

Recommendation

This Form 4 filing details a routine stock option grant to a director, which is a standard compensation practice aimed at aligning interests. It does not provide new material information about the company's financial performance, strategic direction, or operational health that would warrant a change in investment recommendation. Therefore, a "hold" recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell the stock.

Keywords

Alumis Inc., ALMS, Srinivas Akkaraju, stock options, director compensation, SEC Form 4, insider transaction, equity incentive plan, corporate governance